Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University has received a landmark £80 million donation from the Reuben Foundation that will transform Oxford’s newest college and establish a major new scholarship programme for graduate and undergraduate students.

© Alison Stibbe

The University last year established its 39th college – the first for 30 years – as a new base for graduate students who are eager to embrace opportunities for interdisciplinary exchange and apply their research to address key future challenges. Initially named Parks College for its location on Parks Road, the college is now set to become ‘Reuben College’, in recognition of the historic gift that secures its vision of a diverse, dynamic research community working on some of the key issues of our time.

Due to welcome its first students in the autumn of 2021, Reuben College has already attracted an outstanding line-up of academic Fellows. The college aims to generate new insights into the biggest questions of our time by bringing academics from traditionally different disciplines together to work on challenging themes and share their knowledge with the college’s graduate students. A culture of innovation and enterprise and a strong commitment to diversity, sustainability and public engagement will cut across all interdisciplinary activities. The college’s initial research themes are: Artificial Intelligence and Machine Learning; Environmental Change; and Cellular Life, which includes ongoing work in understanding COVID-19 and the current pandemic.

Read more on the University of Oxford website

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.